Abiraterone Proves Efficient Against Prostate Cancer

Abiraterone Proves Efficient Against Prostate Cancer
According to two recent studies, abiraterone, a drug for prostate cancer treatment, was found to increase survival in patients with advanced prostate cancer when given before chemotherapy. These encouraging results were published in Lancet Oncology. A previous study had found that patients that took abiraterone before chemotherapy decreased cancer progression time, but did not improve overall survival, with NICE guidelines rejecting abiraterone treatment before chemotherapy. The results of this study coincide with findings from a clinical trial, recently reported by researchers at The Institute of Cancer Research (ICR) and The Royal Marsden and published in Clinical Cancer Research, that found a subgroup of patients with advanced prostate cancer could benefit from abiraterone given prior chemotherapy. In fact, abiraterone is already in the HS recommendations as a drug prescribed to patients after chemotherapy. In the first study, the research team led by Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Honorary Consultant at The Royal Marsden NHS Foundation Trust, assessed overall survival in a total of 354 patients who received abiraterone before chemotherapy, comparing them with 387 patients who received placebo. The results showed that patients who received abiraterone lived on average 34.7 more months that patients who did not received the drug. Furthermore, results showed that abiraterone is safe, as only a few patients experienced adverse effects. Results from the second study used patients from the same trial, and revealed that abiraterone benefits a subgroup of patients who experience an aggressive type of prostate cancer. Through genetic analysis of tumor samples (spec
Subscribe or to access all post and page content.